In fiscal 2026, which ended Jun 30, 2026, Intelligent Bio Solutions Inc. reported revenue of $4.2 million, up 38.1% from the year before. It recorded a net loss of $12.4 million. The operating loss came to $12.6 million, an operating margin of -299.1%. Diluted earnings per share were -$8.44. Across the 6 fiscal years shown, revenue grew from $2.0 million in fiscal 2021 to $4.2 million in fiscal 2026, about 16.3% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
4
+38.1%
|
3
-1.9%
|
3
+147.6%
|
1
+187.5%
|
0
-77.9%
|
2
|
| Cost of revenue |
2
+19.9%
|
2
+7.1%
|
2
+81.3%
|
1
|
—
|
—
|
| Gross profit |
2
+64.4%
|
1
-12.5%
|
1
+336.4%
|
0
|
—
|
—
|
| Selling, general and administrative |
11
+17.8%
|
9
-3.7%
|
9
+15.3%
|
8
+63.1%
|
5
+46.5%
|
3
|
| Operating income |
-13
-18.1%
|
-11
-3.9%
|
-10
+18.4%
|
-13
-51.1%
|
-8
-49.6%
|
-6
|
| Pretax income |
—
|
—
|
—
|
—
|
—
|
-7
|
| Net income |
-12
-17.6%
|
-11
-4.1%
|
-10
+4.5%
|
-11
-28.0%
|
-8
-18.0%
|
-7
|
| Basic EPS |
-8.44
+57.9%
|
-20.04
-214.1%
|
-6.38
+95.0%
|
-127.00
-1020.9%
|
-11.33
|
—
|
| Diluted EPS |
-8.44
+57.9%
|
-20.04
-214.1%
|
-6.38
+95.0%
|
-127.00
|
—
|
—
|
| Weighted average shares, basic |
1
+179.3%
|
1
-66.9%
|
2
+1802.5%
|
0
-88.6%
|
1
|
—
|
| Weighted average shares, diluted |
1
+179.3%
|
1
-66.9%
|
2
+1802.5%
|
0
|
—
|
—
|
| Other measures | ||||||
| Depreciation and amortization |
1
-3.6%
|
1
+0.5%
|
1
+24.3%
|
1
|
—
|
—
|
| EBITDA |
-11
-20.8%
|
-9
-4.3%
|
-9
+21.9%
|
-12
|
—
|
—
|
| Interest coverage |
-1,174.37x
|
-405.45x
|
—
|
—
|
—
|
—
|
| Margins | ||||||
| Gross margin |
48.63%
|
40.85%
|
45.81%
|
25.99%
|
—
|
—
|
| Operating margin |
-299.11%
|
-349.85%
|
-330.46%
|
-1,002.11%
|
-1,907.11%
|
-281.42%
|
| Pretax margin |
—
|
—
|
—
|
—
|
—
|
-356.49%
|
| Profit margin |
-294.91%
|
-346.23%
|
-326.40%
|
-845.89%
|
-1,900.06%
|
-355.33%
|
| EBITDA margin |
-271.50%
|
-310.28%
|
-291.86%
|
-925.19%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- INBS (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1725430
- Former names
- GBS Inc. (until Oct 18, 2022); Glucose Biosensor Systems (Greater China) Holdings, Inc. (until Sep 19, 2019)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.